These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 29561763)

  • 1.
    Kasten BB; Oliver PG; Kim H; Fan J; Ferrone S; Zinn KR; Buchsbaum DJ
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29561763
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Kasten BB; Gangrade A; Kim H; Fan J; Ferrone S; Ferrone CR; Zinn KR; Buchsbaum DJ
    Nucl Med Biol; 2018 Mar; 58():67-73. PubMed ID: 29413459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B7-H3-targeted
    Kasten BB; Arend RC; Katre AA; Kim H; Fan J; Ferrone S; Zinn KR; Buchsbaum DJ
    Nucl Med Biol; 2017 Apr; 47():23-30. PubMed ID: 28104527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
    Wang X; Osada T; Wang Y; Yu L; Sakakura K; Katayama A; McCarthy JB; Brufsky A; Chivukula M; Khoury T; Hsu DS; Barry WT; Lyerly HK; Clay TM; Ferrone S
    J Natl Cancer Inst; 2010 Oct; 102(19):1496-512. PubMed ID: 20852124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
    Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
    Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer.
    Kim H; Samuel SL; Zhai G; Rana S; Taylor M; Umphrey HR; Oelschlager DK; Buchsbaum DJ; Zinn KR
    Cancer Biol Ther; 2014 Aug; 15(8):1053-60. PubMed ID: 25084100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.
    Eng MS; Kaur J; Prasmickaite L; Engesæter BØ; Weyergang A; Skarpen E; Berg K; Rosenblum MG; Mælandsmo GM; Høgset A; Ferrone S; Selbo PK
    Photochem Photobiol Sci; 2018 May; 17(5):539-551. PubMed ID: 29565434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
    Chan C; Fonge H; Lam K; Reilly RM
    Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2
    Ly S; Anand V; El-Dana F; Nguyen K; Cai Y; Cai S; Piwnica-Worms H; Tripathy D; Sahin AA; Andreeff M; Battula VL
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical evaluation of an
    Kelly VJ; Wu ST; Gottumukkala V; Coelho R; Palmer K; Nair S; Erick T; Puri R; Ilovich O; Mukherjee P
    Theranostics; 2020; 10(15):6946-6958. PubMed ID: 32550914
    [No Abstract]   [Full Text] [Related]  

  • 11. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
    Desroys du Roure P; Lajoie L; Mallavialle A; Alcaraz LB; Mansouri H; Fenou L; Garambois V; Rubio L; David T; Coenon L; Boissière-Michot F; Chateau MC; Ngo G; Jarlier M; Villalba M; Martineau P; Laurent-Matha V; Roger P; Guiu S; Chardès T; Gros L; Liaudet-Coopman E
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
    Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
    J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panitumumab-DOTA-
    Facca VJ; Cai Z; Gopal NEK; Reilly RM
    Mol Pharm; 2022 Oct; 19(10):3652-3663. PubMed ID: 35926098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopy.
    Zhai G; Kim H; Sarver D; Samuel S; Whitworth L; Umphrey H; Oelschlager DK; Beasley TM; Zinn KR
    J Magn Reson Imaging; 2014 Jun; 39(6):1588-94. PubMed ID: 24151215
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Yang R; Lu M; Ming L; Chen Y; Cheng K; Zhou J; Jiang S; Lin Z; Chen D
    Int J Nanomedicine; 2020; 15():9061-9074. PubMed ID: 33239874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
    Jin K; Pandey NB; Popel AS
    Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.
    Suthe SR; Yao HP; Weng TH; Hu CY; Feng L; Wu ZG; Wang MH
    Mol Cancer Ther; 2018 Dec; 17(12):2654-2664. PubMed ID: 30275241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.
    Matossian MD; Burks HE; Elliott S; Hoang VT; Bowles AC; Sabol RA; Wahba B; Anbalagan M; Rowan B; Abazeed ME; Bunnell BA; Moroz K; Miele L; Rhodes LV; Jones SD; Martin EC; Collins-Burow BM; Burow ME
    BMC Cancer; 2019 Mar; 19(1):205. PubMed ID: 30845999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotheranostic Targeting Cancer Stem Cells in Human Colorectal Cancer Xenografts.
    She X; Qin S; Jing B; Jin X; Sun X; Lan X; An R
    Mol Imaging Biol; 2020 Aug; 22(4):1043-1053. PubMed ID: 32125599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.